Literature DB >> 30530101

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Yanling Ren1, Chen Mei1, Li Ye1, Yingwan Luo1, Xinping Zhou1, Haiyang Yang2, Peipei Lin1, Weilai Xu1, Liya Ma1, Jie Jin2, Hongyan Tong3.   

Abstract

We retrospectively analyzed 101 primary MDS patients with complex karyotype during January 2010 and April 2017.The median overall survival (OS) time was 13 (95% CI 9.98-16.02) months, and there was no significant difference in OS for different treatment. Chromosome 5/7 involvement was common (78.22%, 79/101) and associated with shorter OS (12 months vs. 28 months, P < 0.01) Monosomal karyotype (MK) is overlapped with CK in 79 patients, but was not statistically associated with shorter OS. While in 59 cases with genes sequenced, 57 (96.61%) patients were found to have at least one mutation of known significance, and TP53 was the most frequent (74.58%, 44/59), the median OS of patients with TP53 mutation was shorter than those without (10 vs. 27 months, P < 0.01). Multivariate analysis demonstrated that only TP53 mutation was the strongest independent prognostic factor for OS. Moreover, high variant allele frequency (VAF) of TP53 mutation (median VAF was 70.00%) was seen and associated with adverse survival (9 months vs. 13 months, p = 0.04). In conclusion, MDS patients with CK implied an unfavorable outcome regardless of any treatment, TP53 mutation occurs at a high frequency and has a higher VAF, both were associated with worse survival.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complex karyotype; Myelodysplastic syndrome (MDS); TP53 mutation

Mesh:

Substances:

Year:  2018        PMID: 30530101     DOI: 10.1016/j.bcmd.2018.11.006

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  3 in total

1.  Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Authors:  Lingxu Jiang; Lu Wang; Chuying Shen; Shuanghong Zhu; Wei Lang; Yingwan Luo; Hua Zhang; Wenli Yang; Yueyuan Han; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.

Authors:  Lingxu Jiang; Li Ye; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Gaixiang Xu; Haiyang Yang; Chenxi Lu; Yingwan Luo; Shuanghong Zhu; Lu Wang; Chuying Shen; Wenli Yang; Qi Zhang; Yuxia Wang; Wei Lang; Yueyuan Han; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-10       Impact factor: 4.553

3.  Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.

Authors:  An Wu; Panpan Gao; Ningning Wu; Cong Shi; Zhenya Huang; Chunmeng Rong; Ye Sun; Lixia Sheng; Guifang Ouyang; Qitian Mu
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.